• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Spotlight on Fundació ACE

2019-11-29News

This month, we get to know the Fundació ACE centre behind EPAD. The team of Dr. Mercè Boada (principal investigator of the EPAD project in Fundació ACE) began recruiting in June 2019 and has currently recruited over 60 participants in the EPAD Longitudinal Cohort Study (LCS). We caught up with her team and asked them a few questions about their best practices and recruitment strategies.

“EPAD is an innovative and highly ambitious project because it is based on the belief that we’ll get to preventively treat Alzheimer’s disease. This message aims to change the concept of prediction or prevention to the concept of healing.”, said Dr. Mercè Boada.

Any top tips for running the LCS efficiently at your site? We believe that the success of the recruitment relies on the appropriate coordination between our Memory Unit and the Clinical Trials Unit. Continuous communication between both departments and adaptability as well as the willingness to find new synergies are important factors to take into account. Furthermore, we consciously invest a lot of time in the pre-selection process and in the informative visits for possible candidates to whom we explain purposefully the importance of their role in research. Another highly successful activity in line of efficiently running the LCS is the Open House Initiative (OHI), where we offer free cognitive evaluations for individuals from the community worried about their memory. This initiative allows us to have a better chance of finding people willing to participate in research, as they have proactively asked for the test. We have investigated OHI strategy in another IMI project called Models of Patient Engagement for Alzheimer´s Disease (MOPEAD), finding high rates of engagement using this approach. We recommend its implementation for early detection of mild cognitive impairment and preclinical Alzheimer’s disease.

How are you able to find suitable subjects for the cohort? Considering the current inclusion criteria, our main source of participants is the clinical practice of our institution. Thus, last year we evaluated 794 patients diagnosed with mild cognitive impairment that fulfilled the main inclusion criteria of the current algorithm. In addition, we have an extensive database of patients that has been reviewed for the recruitment process. As mentioned before, the Open House Initiative is another effective strategy to find subjects interested in collaborating in Alzheimer´s disease research.

Any country teleconferences/meetings you are organizing and how frequent? Due to our recent inclusion in the project we haven´t organised any country teleconferences or meetings yet. However, we would be very keen to organise and participate in one, as we think it´s a very good idea for the future.
Any past or future events/conference which have been beneficial for recruitment into EPAD? We will keep conducting the Open House Initiative to increase our recruitment potential, in addition to invite the patients that are evaluated in our Memory Unit.

Any activities in terms of participant engagement? We are planning to participate in the EPAD participant´s platform, because it´s in our interest to enhance the role of the participants and listen to their opinions and necessities in order to adapt our practice using a patient-centred approach.

Pictured: Maitee Rosende-Roca, Montse Alegret, Marta Ibarria, Mercè Boada, Charo Cuevas, Carla Abdelnour, Mar Buendía, Carmen Chaler, Liliana Vargas, Lluís Tárraga, Alba Benaque, Esther Pelejà, Adela Orellana, Isabel Hernández, Ana Mauleón, Laura Montrreal, Anna Calvet, Núria Aguilera, Ángela Sanabria, Asunción Lafuente, Marta Marquié, Laia Cañada, Verónica Ferrer, Silvia Gil, Mariola Moreno, Mercedes González, Ester Esteban, Juan Pablo Tartari, Sara Jofresa, Maribel Ramis, Goretti Brunet, María Jesús Allué, Isabel Rodríguez, Marta Lozano, Silvia Preckler, Susana Diego, Ahmad Safiya, Alba Pérez, Ana Pacho, Pilar Canyabate, Miren Gurruchaga y Salvador Almagro.

EPAD Update:

We currently have 27 sites across Europe enrolling and almost 2,000 research participants screened. Congratulations for the site Santander (Spain) for screening their first research participants in November. We are pleased that this site became the latest addition to the EPAD family. In addition, EPAD is pleased to announce the release of a new publication “The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0”. This paper describes the baseline data from the first 500 research participants (V500.0) to assist current and future researchers with their analysis. V500.0 has been collected, quality checked, released and is now available via secure online tools. To access the data, you will need to make an online request by following this link at http://www.ep-ad.org/erap where you will find a variety of resources to support your research.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
2021-04-06
AD Workbench
The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
2021-03-18
EPAD_WordCloud
EPAD releases its first data and sample access bulletin
2021-03-10
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
2 Comments
  1. Pingback: Spotlight on EPAD study site Fundació ACE – Neuronet
  2. Pingback: European Prevention of Alzheimer's Dementia study site Fundació ACE

Comments are closed.

Latest News
  • New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
    2021-04-06
  • AD Workbench
    The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
    2021-03-18
  • EPAD_WordCloud
    EPAD releases its first data and sample access bulletin
    2021-03-10
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

If you're attending #BNA2021, check out the pre-registration poster from @GregorySarah introducing the SPeAk study. Participants of this new study must have previously enrolled in the @IMI_EPAD LCS or CHARIOT Pro study at @CenDemPrevent. #biomarker #Alzheimer’s disease #dementia twitter.com/CenDemPrevent/…

reply retweet favorite
10:18 am · 2021-04-14
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the last @IMI_EPAD publication on the application of the #ATN classification scheme in the first 1500 participants consented in the EPAD Longitudinal Cohort Study. ep-ad.org/2021/04/06/new… @silvia_ingala @IMI_JU @EFPIA @EU_H2020 pic.twitter.com/3HhgMcBDN0

reply retweet favorite
8:15 am · 2021-04-13
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Bioresource consists of over 100,000 samples consisting of blood, CSF, saliva and urine that have been collected annually from research participants throughout their participation in the Longitudinal Cohort Study. #OpenAccess ep-ad.org/2021/03/10/epa… twitter.com/IMI_EPAD/statu… pic.twitter.com/dRjuI1opFi

reply retweet favorite
7:16 am · 2021-04-12
Twitter
EPAD
EPAD
@IMI_EPAD

The ATN classification has been added for public use to the analytical database of the @IMI_EPAD Longitudinal Cohort Study, hosted by @aridhia . ⬇️ ep-ad.org/2021/04/06/new… twitter.com/IMI_EPAD/statu…

reply retweet favorite
5:56 am · 2021-04-07
Twitter
EPAD
EPAD
@IMI_EPAD

In this article, the #ATN classification was operationalized in the first 1500 participants consented in the @IMI_EPAD cohort, a deeply phenotyped cohort of individuals who do not have #dementia. ep-ad.org/2021/04/06/new…

reply retweet favorite
7:08 am · 2021-04-06
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.